Cue Biopharma (CUE) Price & Analysis

Compare

626 Followers

CUE Stock Chart & Stats

$0.72

-$0.18(-11.25%)

At close: Jan 08 4:00 PM EST

$0.72

-$0.18(-11.25%)

Day’s Range― - ―

52-Week Range$0.54 - $1.99

Previous CloseN/A

Volume91.78K

Average Volume (3M)238.59K

Market Cap

$55.42M

Enterprise Value$45.27M

Total Cash (Recent Filing)$27.49M

Total Debt (Recent Filing)$7.63M

Price to Earnings (P/E)―

Beta1.68

Next Earnings

Mar 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding76,845,900

10 Day Avg. Volume365,762

30 Day Avg. Volume238,588

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.82

Enterprise Value/Revenue5.46

Enterprise Value/Gross Profit5.53

Enterprise Value/Ebitda-1.24

Forecast

1Y Price Target

$4.00

Price Target Upside455.56% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Partnership And CollaborationsWith a potential partnership upcoming for CUE-501 and a cash position of $22.5MM, Cue remains an attractive investment opportunity with upside potential if a partnership materializes.

Product DevelopmentCue regained the global rights for CUE-401 from Ono and expects to submit an IND, indicating progress in their product development pipeline.

Bears Say

Clinical Development ChallengesThe presence of confounding variables and lack of a partner may hinder the clinical development progress of CUE-101.

Program DeprioritizationThe company has deprioritized its oncology programs, which may impact its current focus and resources.

Cue Biopharma News

Cue Biopharma, ImmunoScape enter strategic collaboration, license agreement

Cue Biopharma (CUE) and ImmunoScape announced that they have entered into a collaboration and license agreement to advance...

2d ago

CUE

Cue Biopharma Partners with ImmunoScape for Cell Therapy

The latest announcement is out from Cue Biopharma ( ($CUE) ). On November 6, 2025, Cue Biopharma and...

2d ago

CUE

Cue Biopharma Appoints Usman Azam as New CEO

Cue Biopharma ( ($CUE) ) just unveiled an announcement. On September 26, 2025, Cue Biopharma announced the appointment...

1M ago

CUE

Cue Biopharma appoints Usman Azam as CEO

Cue Biopharma (CUE) announced that Usman “Oz” Azam, M.D., has been appointed President and CEO of Cue Biopharma,...

1M ago

CUE

Cue Biopharma initiated with a Buy at Lucid Capital

Lucid Capital analyst Dev Prasad initiated coverage of Cue Biopharma (CUE) with a Buy rating and $4 price...

3M ago

CUE

Cue Biopharma’s Q2 2025: Strategic Advances and Financial Highlights

Cue Biopharma ( ($CUE) ) has released its Q2 earnings. Here is a breakdown of the information Cue...

3M ago

CUE

Cue Biopharma announces initiation of investigator sponsored trial of CUE-102

Cue Biopharma (CUE) announced the initiation of an investigator sponsored trial in rGBM at the DFCI with the...

3M ago

CUE

Cue Biopharma provides clinical update on CUE-101, saw ORR of 50%

Cue Biopharma (CUE) provided a clinical update on its most advanced asset, CUE-101, representative of the CUE-100 series....

4M ago

CUE

Cue Biopharma Amends License Agreement with MIL 40G

Cue Biopharma ( ($CUE) ) just unveiled an announcement. On June 30, 2025, Cue Biopharma, Inc. and MIL...

4M ago

CUE

Cue Biopharma announces presentation of new CUE-101 data

Cue Biopharma (CUE) provided an update on its most advanced clinical stage asset, CUE-101, representative of the CUE-100...

4M ago

CUE

Cue Biopharma receives Pre-IND feedback from FDA for CUE-401

Cue Biopharma (CUE) announced it has received Pre-Investigational New Drug, or Pre-IND, feedback from the FDA. The FDA...

5M ago

CUE

Cue Biopharma CFO Resignation and Board Appointment

Cue Biopharma ( ($CUE) ) has shared an update. On June 4, 2025, Cue Biopharma, Inc. appointed Jill...

5M ago

CUE

Cue Biopharma CFO resigns, CEO to be interim principal financial officer

In a regulatory filing, Cue Biopharma (CUE) disclosed that on June 4, Kerri-Ann Millar notified the company that...

5M ago

CUE

Cue Biopharma reports Q1 EPS (17c), consensus (15c)

Reports Q1 revenue $0.4M, consensus $1.27M. “We made notable and encouraging progress during the first quarter of 2025...

6M ago

CUE

CUE FAQ

What was Cue Biopharma Inc’s price range in the past 12 months?

Cue Biopharma Inc lowest stock price was $0.54 and its highest was $1.99 in the past 12 months.

What is Cue Biopharma Inc’s market cap?

Cue Biopharma Inc’s market cap is $55.42M.

When is Cue Biopharma Inc’s upcoming earnings report date?

Cue Biopharma Inc’s upcoming earnings report date is Mar 24, 2026 which is in 136 days.

How were Cue Biopharma Inc’s earnings last quarter?

Currently, no data Available

Is Cue Biopharma Inc overvalued?

According to Wall Street analysts Cue Biopharma Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cue Biopharma Inc pay dividends?

Cue Biopharma Inc does not currently pay dividends.

What is Cue Biopharma Inc’s EPS estimate?

Cue Biopharma Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cue Biopharma Inc have?

Cue Biopharma Inc has 76,845,900 shares outstanding.

What happened to Cue Biopharma Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Cue Biopharma Inc?

Currently, no hedge funds are holding shares in CUE

Cue Biopharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

-195.55%

Trailing 12-Months

Asset Growth

-3.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cue Biopharma Inc

Cue Biopharma, Inc. is an innovative biotechnology company focused on developing biologic therapies to harness the power of the immune system to treat cancer and autoimmune diseases. The company operates in the biopharmaceutical sector and specializes in its proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform, which enables the selective modulation of T cell responses to target specific disease mechanisms. Cue Biopharma's core products include its clinical-stage therapies, which are designed to enhance immune responses against tumors while minimizing off-target effects.

Cue Biopharma (CUE) Earnings & Revenues

Historic Earnings Reports

CUE Stock 12 Month Forecast

Average Price Target

$4.00

▲(455.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Jan<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.72,0.9723076923076923,1.2246153846153847,1.476923076923077,1.7292307692307693,1.9815384615384617,2.2338461538461543,2.4861538461538464,2.7384615384615385,2.9907692307692306,3.2430769230769236,3.4953846153846158,3.747692307692308,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.72,0.9723076923076923,1.2246153846153847,1.476923076923077,1.7292307692307693,1.9815384615384617,2.2338461538461543,2.4861538461538464,2.7384615384615385,2.9907692307692306,3.2430769230769236,3.4953846153846158,3.747692307692308,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.72,0.9723076923076923,1.2246153846153847,1.476923076923077,1.7292307692307693,1.9815384615384617,2.2338461538461543,2.4861538461538464,2.7384615384615385,2.9907692307692306,3.2430769230769236,3.4953846153846158,3.747692307692308,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.9,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.75,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >